News

Press Releases

Featured
OncoNano Medicine To Present a Trials in Progress Poster for ONM-501 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024
OncoNano Medicine to Present Late-Breaking Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
OncoNano Medicine Appoints Kartik Krishnan as Chief Executive Officer and Promotes Melissa Paoloni to Chief Operating Officer
OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas
OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research & Development
OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting
OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study
OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation at 2023 ASCO Annual Meeting
OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR Annual Meeting 2023
OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care
OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023
OncoNano Medicine’s Pegsitacianine Granted Breakthrough Therapy Designation for Real-Time Surgical Imaging by the Food and Drug Administration
OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at SITC Annual Meeting
OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting
OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis
OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference
OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022
OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer
OncoNano Medicine Announces the Appointment of Elina Lavit as Vice President, Business Development
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting
OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting
OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
OncoNano Medicine Appoints Brett Giroir, M.D., to Board of Directors
$18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas
Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study
Positive Preclinical Data for ONM-501 at AACR Virtual Conference